MARKET

CTNM

CTNM

Contineum Therapeutics
NASDAQ
13.88
+0.07
+0.51%
Closed 16:00 03/06 EST
OPEN
14.71
PREV CLOSE
13.81
HIGH
15.03
LOW
13.48
VOLUME
191.88K
TURNOVER
--
52 WEEK HIGH
16.33
52 WEEK LOW
3.350
MARKET CAP
518.22M
P/E (TTM)
-6.1533
1D
5D
1M
3M
1Y
5Y
1D
Contineum Therapeutics Is Maintained at Outperform by Baird
Dow Jones · 2d ago
Contineum Therapeutics Price Target Raised to $20.00/Share From $14.00 by Baird
Dow Jones · 2d ago
Baird Maintains Outperform on Contineum Therapeutics, Raises Price Target to $20
Benzinga · 2d ago
RBC Capital Remains a Buy on Contineum Therapeutics, Inc. Class A (CTNM)
TipRanks · 2d ago
Stifel Nicolaus Keeps Their Buy Rating on Contineum Therapeutics, Inc. Class A (CTNM)
TipRanks · 2d ago
Contineum price target raised to $20 from $14 at Baird
TipRanks · 2d ago
Analysts Offer Insights on Healthcare Companies: Climb Bio (CLYM), ArriVent BioPharma, Inc. (AVBP) and Contineum Therapeutics, Inc. Class A (CTNM)
TipRanks · 2d ago
CONTINEUM THERAPEUTICS INC - MAY OFFER CLASS A COMMON STOCK UP TO $100 MLN THROUGH LEERINK PARTNERS - SEC FILING
Reuters · 3d ago
More
About CTNM
Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I) indications with significant unmet need. It is advancing a pipeline of internally developed programs with multiple drug candidates in clinical trials. Its lead asset, PIPE-791, is a novel, brain-penetrant, small-molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) in development for idiopathic pulmonary fibrosis (IPF), progressive multiple sclerosis (PrMS), and chronic pain. Its second drug candidate, PIPE-307, is a novel, small-molecule selective inhibitor of the muscarinic type 1 receptor (M1R), in development for depression and relapse-remitting multiple sclerosis (RRMS). The Company is also conducting preclinical and discovery-phase experiments targeting other NI&I indications where its internally discovered molecules may have therapeutic potential.

Webull offers Contineum Therapeutics Inc stock information, including NASDAQ: CTNM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTNM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CTNM stock methods without spending real money on the virtual paper trading platform.